Information Provided By:
Fly News Breaks for October 8, 2015
BMRN, VRTX, PFE, GILD, LLY, BMY, BIIB, RXDX, OTIC, LBIO, FLKS, BLUE, GWPH, AMGN, CELG, ALXN
Oct 8, 2015 | 06:32 EDT
Piper Jaffray's team of Biopharma analysts, led by Joshua Schimmer, explain this morning in research note to investors why they believe drug prices are justifiable. The "fairly lopsided" drug-pricing discussion "noise" has created attractive entry points for stocks in the sector, the analysts argue. They say that after adjusting for actual inflation, the growth of drug prices "does not seem particularly concerning." The current dialogue on the topic under-emphasizes the need to provide "extremely attractive incentives" for companies to embark on the "highly risky, capital-intensive, long-development cycle drug development path which is needed to bring new cures for important diseases," the analysts contend. Schimmer's top picks are Alexion (ALXN), Celgene (CELG) and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC) and Ignyta (RXDX) in the small-cap sector.
News For ALXN;CELG;AMGN;GWPH;BLUE;FLKS;LBIO;OTIC;RXDX;BIIB;BMY;LLY;GILD;PFE;VRTX;BMRN From the Last 2 Days
LLY
Mar 18, 2024 | 10:41 EDT
Oprah Winfrey is hosting a television special on Monday to discuss how WeightWatchers (WW) and weight loss drugs helped her with weight and obesity, CNN's Lisa Respers France reports. "An Oprah Special: Shame, Blame and the Weight Loss Revolution" will be a sit-down conversation around the "radical impact of prescription weight loss medications," according to promotional material for the special. Winfrey, who recently exited the board of WW, will moderate the conversation in front of a live audience with medical experts to explore "prevailing questions and concerns surrounding the impact on our health care, economy, lifestyle and culture," according to a press release for the event. "It is a very personal topic for me and for the hundreds of millions of people impacted around the globe who have for years struggled with weight and obesity," Winfrey said. Weight loss drug options include Eli Lilly's (LLY) Mounjaro and Novo Nordisk's (NVO) Ozempic. Reference Link